Abstract

SAFETY AND EFFICACY OF CINNAMOMUM ZEYLANICUM BLUME (DÄ€RCHIÌ—NIÌ„) IN NON-ALCOHOLIC FATTY LIVER DISEASE: A SINGLE-BLIND RANDOMIZED STANDARD CONTROLLED TRIAL

Fouzia Farooq*, Dr. Zaffar Hussain, Mir Idrees Hanief and Zarfah Fida

.

Abstract

Non-alcoholic fatty liver disease is the most common chronic liver disease worldwide, where in, there is accumulation of fat in hepatocytes, detected either by liver imaging or histology without the evidence of any secondary causes of hepatic fat accumulation. It affects 25% of the adult population globally and its prevalence varies from 9% to 32% in India. Although it is a highly prevalent disorder, there is no Food and Drug Administration approved treatment for it. The present study was designed to compare the safety and efficacy of Cinnamomum zeylanicum Blume and vitamin E in its management. Sixty diagnosed patients were randomly assigned into test and control group (30 patients in each group). Patients in the test group were administered D r 500 mg capsules twice daily and the patients in the control group were given vitamin E 400 mg capsules twice daily for 60 days. Objective parameters USG, LFT & Lipid profile were assessed before and after the treatment. Follow up was done every 15 days of the study for the assessment of subjective parameters (dull ache in right hypochondrium, dyspepsia, anorexia, malaise). The test group exhibited significant improvement in subjective parameters. The results were comparable in the case of a dull ache in the right hypochondrium and malaise (p-value 0.718 and 0.183). Whereas, in case of dyspepsia and anorexia, the test group showed excellent results (p-value of 0.05). Conclusion: The test drug Cinnamomum zeylanicum Blume (Dārchi̗nī) is equally effective and safe in treating Non-alcoholic fatty liver disease in comparison to vitamin E.

Keywords: NAFLD, Hepatic steatosis, Da?rchi?ni?, Cinnamomum zeylanicum Blume.